“Press release, press release! OS-imertinib and chemo are making the oncology Jumbotron today — and with a very hot play on OS they have nothing to hide.”
— Balazs Halmos, MD (@BalazsHalmosMD), on the FLAURA2 OS readout
The problem: every lung readout now arrives wrapped in a press release and a wave of enthusiastic posts. The agitation: the two voices the field relied on to pressure-test that enthusiasm have left the independent-academic stage. The fix: know who is stepping into the skeptic role — before their questions set how the next readout is received.
In our lung-cancer influence map, two names long anchored the skeptic role. Both have moved on. Dr. Jack West joined Summit Therapeutics as VP of Clinical Development — working on ivonescimab, a bispecific now in front-line trials — so that voice speaks from industry. And Dr. Vinay Prasad served as the FDA’s CBER Director and Chief Medical & Scientific Officer before returning to UCSF in 2026. The high-reach, independent-skeptic role is open — and someone always fills it.
Skeptics aren’t contrarians — they’re the methodologists who ask the questions every thoughtful oncologist is quietly thinking: Is the endpoint a surrogate? Is the OS data mature, or 31% mature? How much crossover was allowed in the control arm? Is this cost-effective? Is ‘practice-changing’ earned, or a press-release line? Their take often decides whether a positive trial is adopted enthusiastically or cautiously. For a medical-affairs team, knowing who is raising those questions — and being ready with a substantive answer — is the difference between leading a scientific exchange and being caught flat.
Ranked from our lung dataset by skeptic-style, debate-driving posts (high replies and quotes on endpoint, maturity, crossover, and value questions), these independent academics are already filling the gap — each shown with a real verbatim post and the engagement it drew:
Dr. Gyawali is the closest to a direct heir — a globally followed methodologist whose surrogate-endpoint and value critiques carry Prasad-level reach. Dr. Halmos brings the press-release skepticism live from the conference floor; Dr. Forde models the balanced critic, crediting the win while flagging crossover and immature OS; Dr. Shah and Dr. Addeo press on trial design and clinical nuance from Europe. None has consolidated the role yet — which is exactly why this is a list to watch, not a settled ranking.
And the bench keeps thinning: beyond West and Prasad, Dr. Nathan Pennell — whose ADAURA cost-effectiveness work was a model of the value lens — left Cleveland Clinic in August 2025 to become SVP, Worldwide Head of Hematology/Oncology Medical Affairs at Bristol Myers Squibb. Industry and regulators keep recruiting exactly the rigorous academics who shaped these debates — which is precisely why the independent-skeptic role is worth watching, not assuming.
Filter the lung influence network to debate-driving engagement — replies and quotes, not just impressions — on the trials you cover, then watch which independent academics are climbing. Feed their verbatim takes into your AI prep tool before a congress so you walk in ready for the hard questions, not surprised by them. The ELCC 2026 influence network is built for exactly this kind of filtering.
With Jack West now at Summit Therapeutics and Vinay Prasad having served at the FDA, the most active independent academic methodologists in lung-trial debate include Dr. Bishal Gyawali, Dr. Balazs Halmos, Dr. Patrick Forde, Dr. Riyaz Shah, and Dr. Alfredo Addeo.
The field’s two most-networked skeptics changed roles: Dr. Jack West joined Summit Therapeutics (industry), and Dr. Vinay Prasad served as the FDA’s CBER Director and Chief Medical & Scientific Officer before returning to UCSF in 2026.
Skeptics shape how a readout is received — pressing on endpoints, OS maturity, crossover, and value. Knowing who raises those questions, and where, lets a team prepare substantive answers before the field’s opinion sets.
Rank by debate-driving engagement (replies and quotes) on endpoint, maturity, crossover, and value posts — not raw impressions. A live influence map surfaces independent academics gaining reach on those questions in real time.
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Engagement, impressions, and verbatim quotes are real figures from the KOL Pulse database. Last updated June 2026.
Brian Shields : Jul 1, 2026 8:15:47 AM
“Combination therapy shows over ONE-YEAR mOS improvement compared to osimertinib alone. Key data to discuss with patients in clinic—but does this...
Brian Shields : Jun 28, 2026 11:07:03 AM
“Your physicians are already asking AI about your competitors’ trials — can that AI even read your KOL intelligence?”
Brian Shields : May 23, 2024 5:52:56 AM
by Brian Shields